Literature DB >> 1304868

Role of histidine residues in the alpha-bungarotoxin binding site of the nicotinic acetylcholine receptor.

H D Lacorazza1, M S Otero de Bengtsson, M Biscoglio de Jiménez Bonino.   

Abstract

This paper studies the effect of histidine chemical modification of the membrane-bound acetylcholine receptor from Discopyge tschudii on its specific alpha-bungarotoxin binding. The acylating reagent ethoxyformic anhydride (diethyl pyrocarbonate, DEP), was used. DEP-treatment induces a loss of binding capacity, time and DEP-concentration dependent. After a 30 min period of derivatization with 2 mM final DEP-concentration, at pH 7.4, the decrease reaches 70%; the loss of binding capacity is faster at pH 7.4 than at pH 6.0, as expected, since the amount of unprotonated species is higher under the first condition. Moreover, when ethoxyformylation is carried out at different pH values, the most important neurotoxin binding decrease occurs between pH 6.0 and 8.0. Furthermore, ethoxyformylation reversion restores such capacity. Consistent with the modification of a binding site, the ethoxyformylation does not bear on the affinity but reduces the number of receptors. Ethoxyformylation in the presence of carbamylcholine shows some ligand protective effect. These results, as a whole, strongly indicate a relevant role for histidine residues at the alpha-bungarotoxin binding site of the nicotinic acetylcholine receptor.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1304868     DOI: 10.1016/0197-0186(92)90031-l

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  2 in total

1.  Effect of chemical modification of extracellular histidyl residues on the channel properties of the nicotinic acetylcholine receptor.

Authors:  C B Bouzat; H D Lacorazza; M Biscoglio de Jiménez Bonino; F J Barrantes
Journal:  Pflugers Arch       Date:  1993-06       Impact factor: 3.657

2.  Circulating antibodies against nicotinic acetylcholine receptors in chagasic patients.

Authors:  J C Goin; G Venera; M Biscoglio de Jiménez Bonino; L Sterin-Borda
Journal:  Clin Exp Immunol       Date:  1997-11       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.